论文部分内容阅读
目的观察舒血宁联合低分子肝素钙治疗不稳定型心绞痛的疗效与安全性。方法 85例患者随机分为两组,治疗组42例,对照组43例,两组均常规治疗和使用低分子肝素钙,治疗组在对照组的基础上加用舒血宁注射液10ml静脉滴注,2次/d,14d后分别观察两组心绞痛、心电图改善疗效。结果治疗组在心绞痛控制、心电图ST段及T波改善方面与对照组比较差异有统计学意义(P<0.05);两组均无严重不良反应发生。结论舒血宁注射液联合低分子肝素钙治疗不稳定型心绞痛,能明显改善不稳定心绞痛发作,近期疗效优于单用低分子肝素钙,不良反应无增加。
Objective To observe the efficacy and safety of Shuxuening combined with low molecular weight heparin in the treatment of unstable angina pectoris. Methods 85 patients were randomly divided into two groups, 42 cases in the treatment group and 43 cases in the control group. The two groups were treated routinely with low molecular weight heparin, and the treatment group was treated with 10ml Shuxuening injection on the basis of the control group Note, 2 times / d, 14d were observed after two groups of angina pectoris, ECG to improve the curative effect. Results There was significant difference between the treatment group and control group in the control of angina pectoris, ST segment of ECG and T wave improvement (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Shuxuening injection combined with low molecular weight heparin calcium in the treatment of unstable angina pectoris can obviously improve the onset of unstable angina pectoris. The recent curative effect is superior to that of single low molecular weight heparin calcium, with no increase of adverse reactions.